RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Nasopharyngeal Carcinoma: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Second primary malignancies after nasopharyngeal carcinoma: a systematic review and meta-analysis of 35 cohort studies
WangHehui, Open Science Framework (16 October 2026)
https://doi.org/10.17605/osf.io/xh3w4
- 2.
Research on the molecular mechanisms and therapeutic strategies of reactive oxygen species in nasopharyngeal carcinoma
Yuting Gu et al., Frontiers in Pharmacology (16 October 2026)
https://doi.org/10.3389/fphar.2026.1980464
- 3.
Integrated Serum and Spatial Metabolomics Reveals Compartmentalized Metabolic Reprogramming and Ferroptosis Susceptibility in Nasopharyngeal Carcinoma
Huiling Hong et al., Metabolites (16 October 2026)
https://doi.org/10.3390/metabo16100783
- 4.
Local therapy to recurrent/metastatic foci augments the benefit of immune checkpoint inhibitors in nasopharyngeal carcinoma.
Chen Xueqin et al., European journal of cancer (Oxford, England : 1990) (16 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42721861/
- 5.
Ozonated water mouthrinse for radiation-induced oral mucositis in non-keratinizing nasopharyngeal carcinoma: a retrospective cohort study.
Yu Jing et al., Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (16 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42886273/
Clinical Trials : Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials. Each has its ID and full eligibility criteria at the link shown.
- 1.
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
NCT06029270 · Recruiting · Phase 2 · National Cancer Institute (NCI)
Ages 18 and over
https://clinicaltrials.gov/study/NCT06029270
- 2.
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
NCT06064097 · Recruiting · Phase 2 · National Cancer Institute (NCI)
Up to age 21
https://clinicaltrials.gov/study/NCT06064097
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Nasopharyngeal Carcinoma
Nasopharyngeal carcinoma is a cancer that starts in the nasopharynx, the space behind the nose and above the back of the throat. It is strongly linked with Epstein-Barr virus infection and may cause a neck lump, blocked nose, nosebleeds or hearing changes. Treatment usually involves radiotherapy, often combined with chemotherapy, and long-term follow-up is important.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
Retrospectively submitted registration (research concluded). We conducted a systematic review and random-effects meta-analysis of the incidence and risk of second primary malignancy (SPM) after nasopharyngeal carcinoma (NPC). Searches: PubMed/MEDLINE, Web of Science, Cochrane (CDSR+CENTRAL), CNKI, Embase, to 16 Oct 2026; 35 studies included (~538 records screened, >130,000 patient records). Primary outcome: standardized incidence ratio (SIR) of SPM after NPC. Pooled SIR 1.84 (95% CI 1.29-2.63, I2=93.2%); 5-year cumulative incidence 2.65% (0.90-7.52%); IMRT-era cohorts homogeneous (SIR 1.89, I2=0%); Egger p=0.71.
Common Questions
What is Nasopharyngeal Carcinoma?
Nasopharyngeal carcinoma is a cancer that starts in the nasopharynx, the space behind the nose and above the back of the throat. It is strongly linked with Epstein-Barr virus infection and may cause a neck lump, blocked nose, nosebleeds or hearing changes. Treatment usually involves radiotherapy, often combined with chemotherapy, and long-term follow-up is important.
How many clinical trials are available for Nasopharyngeal Carcinoma?
RareWays currently indexes 729 clinical trials for Nasopharyngeal Carcinoma, of which 137 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Nasopharyngeal Carcinoma come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Nasopharyngeal Carcinoma.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.